Janina Niggenaber

Janina Niggenaber

Auto-generated profile, based on publicly available information

Janina Niggenaber

Faculty of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JNJanina Niggenaber
Janina Niggenaber
LHLeonie Heyden
Leonie Heyden
TGTobias Grabe
Tobias Grabe
MMMatthias P. Müller
Matthias P. Müller
JLJonas Lategahn
Jonas Lategahn
DRDaniel Rauh
Daniel Rauh

4 October 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
JLJonas Lategahn
Jonas Lategahn
MKMarina Keul
Marina Keul
PKPhilip Klövekorn
Philip Klövekorn
HTHannah L. Tumbrink
Hannah L. Tumbrink
JNJanina Niggenaber
Janina Niggenaber
DRDaniel Rauh
Daniel Rauh
We present inhibitors of drug resistant mutants of EGFR including T790M and C797S. In addition, we present the first X-ray crystal structures of covalent inhibitors in complex with C797S-mutated EGFR to gain insight into their binding mode.

2 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ATA. Teuber
A. Teuber
TST. Schulz
T. Schulz
BFB. S. Fletcher
B. S. Fletcher
RGR. Gontla
R. Gontla
TMT. Mühlenberg
T. Mühlenberg
DRD. Rauh
D. Rauh
Avapritinib is the only potent and selective inhibitor approved for the treatment of D842V-mutant gastrointestinal stromal tumors (GIST), the most common primary mutation of the platelet-derived growth factor receptor α (PDGFRA). The approval was based on the NAVIGATOR trial, which revealed overall response rates of more than 90%. Despite this transformational activity, patients eventually progress, mostly due to acquired resistance mutations or following discontinuation due to neuro-cognitive side effects. These patients have no therapeutic alternative and face a dismal prognosis. Notable, little is known about this drug’s binding mode and its medicinal chemistry development, which is instrumental for the development of the next generation of drugs. Against this background, we solve the crystal structures of avapritinib in complex with wild-type and mutant PDGFRA and stem cell factor receptor (KIT), which provide evidence and understanding of inhibitor binding and lead to the identification of a sub-pocket (Gα-pocket). We utilize this information to design, synthesize and characterize avapritinib derivatives for the determination of key pharmacophoric features to overcome drug resistance and limit potential blood-brain barrier penetration.

29 April 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JLJonas Lategahn
Jonas Lategahn
HTHannah L. Tumbrink
Hannah L. Tumbrink
CSCarsten Schultz-Fademrecht
Carsten Schultz-Fademrecht
AHAlena Heimsoeth
Alena Heimsoeth
LWLisa Werr
Lisa Werr
DRDaniel Rauh
Daniel Rauh

18 April 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TGTobias Grabe
Tobias Grabe
KJKirujan Jeyakumar
Kirujan Jeyakumar
JNJanina Niggenaber
Janina Niggenaber
TSTom Schulz
Tom Schulz
SKSandra Koska
Sandra Koska
DRDaniel Rauh
Daniel Rauh

15 August 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JNJanina Niggenaber
Janina Niggenaber
JHJulia Hardick
Julia Hardick
JLJonas Lategahn
Jonas Lategahn
DRDaniel Rauh
Daniel Rauh